MIRA INFORM REPORT

 

 

Report Date :

05.03.2014

 

IDENTIFICATION DETAILS

 

Name :

CFR PHARMACEUTICALS S.A.

 

 

Registered Office :

Pedro de Valdivia 295 Providencia, Santiago / XIII Región Metropolitana

 

 

Country :

Chile

 

 

Financials (as on) :

30.09.2013

 

 

Date of Incorporation :

08.09.2010

 

 

Legal Form :

Joint-Stock Company

 

 

Line of Business :

Investment and Consultancy Company

 

 

No of Employees :

5120

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 18,002,781

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow But Correct

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – december 01, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

Chile

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

CHILE - ECONOMIC OVERVIEW

 

Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports of goods and services account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2013, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and nine other countries in negotiating the Trans-Pacific-Partnership trade agreement. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD.

Source : CIA

 


 

IDENTIFICATION

 

 

CORRECT COMPANY NAME

CFR PHARMACEUTICALS S.A.

TRADE NAME

CRF S.A / CFR

TAXPAYER REGISTRATION

RUT 76116242

MAIN ADDRESS

Pedro de Valdivia 295 Providencia

DEPT/PROV/REGION/STATE

Santiago / XIII Región Metropolitana

COUNTRY

CHILE

TELEPHONE

(562) 23505214 - 23505200

CORPORATE E-MAIL

contact@cfr-corp.com

WEB

www.cfr-corp.com

COMMENTS

 

Neither address nor telephone number was given on your order.
Fax: (562) 23505212

 

 

EXECUTIVE SUMMARY

 

 

Date of foundation

2010

Capital stock

US$.1,279,257,511.= Dollars

Shareholders' equity

344,310,104,000.00 Pesos (31DEC2012)

Annual revenues

US$ 570,831,999.58 Pesos (31DEC2012)

Profits (loss)

37,110,644,000.00 Pesos (31DEC2012)

permanent employees

7

Chief Executive

WEINSTEIN MANIEU, ALEJANDRO ESTEBAN

Disposition

C: Poor. Very few information was given. Politely.

Payments policy

P5: Without rating (No payment experience traced)

Credit (**)

A+ : With no Risk, Reliable, Solvent, Profiatble, Good Financial Situation.

Number of times that this company was required: 2

 

 

REPUTATION

 

NOTHING AGAINST COMPANY

 

 

CREDIT OPINION

 

 

Requested credit

Maximum Credit

Suggested credit (*)

Open

(*) Opinion after analyzing different factors and other opinions.

 

 

LEGAL STRUCTURE

 

 

 

 

 

LEGAL STATUS

Joint-Stock Company

 

 

DATE OF INCORPORATION

08SEP2010

 

 

PLACE OF REGISTRY

Santiago

 

 

 

NOTARY OFFICE

Verónica Torrealba Costabal

DURATION

Perpetual

 

INITIAL CAPITAL

Ps$75,000,000.= Pesos

 

 

 

CURRENT PAID-IN CAPITAL

US$.1,279,257,511.= Dollars

LAST CAPITAL INCREASE

22/07/2013

 

SHAREHOLDERS EQUITY

344,310,104,000.00 Pesos (31DEC2012)

 

 

 

CURRENT EXCHANGE RATE (US$)

Ps$.561.32 per USD.1.00

 

 

 

COMMENTS

 

 

 

Incorporation of the Company was published on the Official Gazette on l 16/09/2010, Page 3.
 
 
In accordance with Notarial Act dated  30/09/2010 before Iván Torrealba Acevedo Notary Public of Santiago, published on the Official Gazette on  10/12/2010 Page  N° 8, capital stock was increased from Ps$75,000,000,000.- to the sum of Ps$113,423,000.- divided into 113,283,423,000 registered shares without nominal value. 
 
In accordance with Notarial Act dated  14/12/2010 before Iván Torrealba Acevedo Notary Public of Santiago, published on the Official Gazette on  18/12/2010 Page  N° 6, capital stock was increased 1) It was resolved, among other things, substitute, as from  30/09/2010, the currency of the capital stock from Chilean Pesos to US$ Dollars, thus, capital stock amounts to US$.234,226,037.- 2) reduce, as from that date, the number of shares from  113,283,423,000 to 6,720,000,000 registered shares without nominal value. Likewise, capital stock was increased to the sum of US$.308,219,370.- divided into  8,512,000.000 registered shares without nominal value.  Finally, the Bylaws were amended and new Consolidated Text was established, under which the name of the Company is CFR Pharmaceuticals S.A., t/a CFR S.A. and/or CFR, domiciled in Santiago, for an indefinite period. 
 
In accordance with Notarial Act dated  30/03/2011 before José Musalem Saffie, Notary Public of Santiago, published on the Official Gazette on  29/04/2011, business purpose was changed and expanded. 
In accordance with Notarial Act dated  29/04/2011 before Iván Torrealba Acevedo, Notary Public of Santiago, published on the Official Gazette on  13/05/2011, the Bylaws were amended, under which they ruled out the possibility to use for commercial purpose the trade names CFR S.A. and/or CFR.   Therefore, the new Consolidated text confirmed the name of the Company - CFR Pharmaceuticals S.A., being able to use for banking and advertising purpose the trade name CFR  S.A. or for promotion purpose, the abbreviated form - CFR. 
 
In accordance with Notarial Act dated 29/04/2013 before Gustavo Montero Marti, Notary Public of Santiago, published on the Official Gazette on 08/05/2013, capital stock was increased to the sum of US$.725,293,582.-Dollars divided into 9,237,000,000 registered shares without nominal value 
 
In accordance with Notarial Act dated  22/07/2013 before Veronica Torrealba Costabal, Notary Public of Santiago, published on the Official Gazette on 30/07/2013, capital stock was increased to the sum of US$.1,279,257,511 Dollars.
 
In accordance with Notarial Act dated  21/10/2013 before Iván Torrealba Acevedo, Notary Public of Santiago, published on the Official Gazette on  24/10/2013, the Bylaws were amended  concerning matters that are not part of this extract. 
The 4.43% of the capital stock is controlled by other minority shareholders.

 

DIRECTORS - EXECUTIVES – SHAREHOLDERS

 

FULL NAMES / COMPANY NAME

TITLE

%PART.

SINCE

VARGAS MUŃOZ, PATRICIO

Vice President

 

 

WEINSTEIN CRENOVICH, ALEJANDRO KOSTIA

Director

 

 

GUZMAN MOLINARI, JUAN ANTONIO

Director

 

 

WEINSTEIN MANIEU, NICOLAS FRANCISCO

Director

 

 

BILBAO HORMAECHE, JUAN CRUZ DOMINGO

Director

 

 

TAGLE QUIROZ, GUILLERMO ARTURO

Director

 

 

EGUIGUREN CORREA, ALBERTO

Director

 

 

SHOHET, ELIAHU

Director

 

 

WEINSTEIN MANIEU, ALEJANDRO ESTEBAN

General Manager

 

 

CAHN SAUERTEIG, ALEXANDER

Finance Manager

 

 

ESPINOZA OVALLE, JULIO

Corporate Manager

 

 

EGUIGUREN CORREA, AGUSTIN

Executive

 

 

INVERSIONES QUARK LTDA.

Shareholder / Member

5.96%

 

THE BANK OF NEW YORK

Shareholder / Member

5.85%

 

BANCO DE CHILE POR CUENTA DE TERCEROS CA.

Shareholder / Member

5.29%

 

BANCO SANTANDER POR CUENTA DE INV EXTRANJEROS

Shareholder / Member

3.65%

 

INVERSIONES PHOTON LTDA.

Majority Shareholder (Parent Company)

53.32%

 

INVERSIONES QUANTUM LTDA.

Shareholder / Member

13.91%

 

COMPAŃIA DE SEGUROS DE VIDA CONSORCIO NACIONAL SEGUROS S.A.

Shareholder / Member

0.62%

 

BANCO ITAU POR CUENTA DE INVERSIONISTAS

Shareholder / Member

3.24%

 

MONEDA S.A.A.F.I. PARA PIONERO F.I.M.

Shareholder / Member

1.51%

 

LARRAIN VIAL S.A. CORREDORES DE BOLSA

Shareholder / Member

1.05%

 

BANCHILE ADMINISTRADORA GENERAL DE FONDOS S.A.

Shareholder / Member

0.65%

 

AFP HABITAT S.A. FONDO TIPO C

Shareholder / Member

0.52%

 

 

 

WHO IS WHO?

 

VARGAS MUŃOZ, PATRICIO

 

TITLE

Vice President

 

TAX ID

122327159

 

 

 

 

 

 

 

GUZMAN MOLINARI, JUAN ANTONIO

 

TITLE

Director

 

TAX ID

51239180

 

 

 

 

 

 

 

WEINSTEIN MANIEU, NICOLAS FRANCISCO

 

TITLE

Director

 

TAX ID

59208713

 

 

 

 

 

 

 

BILBAO HORMAECHE, JUAN CRUZ DOMINGO

 

TITLE

Director

 

TAX ID

6348511K

 

 

 

 

 

 

 

TAGLE QUIROZ, GUILLERMO ARTURO

 

TITLE

Director

 

TAX ID

80892233

 

 

 

 

 

 

 

EGUIGUREN CORREA, ALBERTO

 

TITLE

Director

 

TAX ID

99790687

 

 

 

 

 

 

 

WEINSTEIN MANIEU, ALEJANDRO ESTEBAN

 

TITLE

General Manager

 

NATIONALITY

Chilean

 

D.O.B.

10FEB1958

 

PROFESSION

Commercial Engineer

 

TAX ID

59208705

 

BACKGROUND INFORMATION

Commercial Engineer, Business Administrator and Auditing Accountant from  Pontificia Universidad Católica de Chile and OPM from Harvard Business School (USA).
 
Member of several boards of directors of pharmaceutical companies in Latin American, Europe and Southeast Asia, as well as in Chile.

 

REFERENCES

 

According to source B.C.R.A., he is not reported with any banking debt over the last 24 months.

 

 

 

 

ASSOCIATED AS PER OUR DATABASE TO

 

 

 

COMPANY

TITLE

TAX REG

COUNTRY

LABORATORIOS NORTHIA S.A.C.I.F.

President

30515608210

ARGENTINA

LABORATORIOS RECALCINE S.A.

General Manager

916370008

CHILE

CFR CORPORACION FARMACEUTICA RECALCINE

General Manager

 

CHILE

 

 

 

 

 

 

PARTICIPATED IN

 

COMPANY

TITLE

COUNTRY

YEAR / REF

PHARMALAB S.A. (BAJA DEFINITIVA

 

PERU

 

 

 

 

 

CAHN SAUERTEIG, ALEXANDER

 

TITLE

Finance Manager

 

TAX ID

109964239

 

 

 

 

ASSOCIATED AS PER OUR DATABASE TO

 

COMPANY

TITLE

TAX REG

COUNTRY

ARAUCO PERU S.A.

 

20379251286

PERU

 

 

 

 

 

 

 

ESPINOZA OVALLE, JULIO

 

TITLE

Corporate Manager

 

TAX ID

109316989

 

 

 

 

 

 

 

EGUIGUREN CORREA, AGUSTIN

 

TITLE

Executive

 

TAX ID

11472453K

 

 

 

 

 

 

 

 

BUSINESS HISTORY

 

Through its direct affiliates CFR CHILE S.A. y CFR INTERNATIONAL SPA, the Company takes part in more than 100 companies in 19 countries.  In Chile the main producer and trader is LABORATORIOS RECALCINE S.A.

 

 

RELATED COMPANIES TO SUBJECT COMPANY OR TO MAJORITY SHAREHOLDER

 

COMPANY NAME

COUNTRY

TAX REG.

RELATION %

ATLAS FARMACEUTICA S.A.

ARGENTINA

(AC) 33703936429

Related

CFR CHILE S.A.

CHILE

(AC) 761162195

Related

CFR CORPORACION FARMACEUTICA RECALCINE

CHILE

 

Related

CFR INTERNATIONAL SPA

CHILE

(AC) 761162624

Related

INVERSIONES K2 SPA

CHILE

(AC) 761162071

Related

LABORATORIOS NORTHIA S.A.C.I.F.

ARGENTINA

(AC) 30515608210

Related

LABORATORIOS RECALCINE S.A.

CHILE

(AC) 916370008

Related

 

BUSINESS

 

SIC Classification

D - BANCA-SEGUROS-AFP-INVERSIONES-OFFSHORE (Intermediación financiera en bancos comerciales, Seguros generales, AFP, inversiones y colocaciones, empresas offshore)

 

 

Main activity

Investment and consultancy company.

 

O P E R A T I O N S

 

Import

Yes

 

Country

Spain, India and Vietnam, occasionally

 

Export

No

 

% CASH SALES / METHOD

100%

 

% Ventas exterior (Paises)

01%

 

% DOMESTIC PURCHASES

Yes

% FOREIGN PURCHASES

Yes

SELLING TerritorY

Domestic market - 99%

 

EMPLOYEES

7

 

 

 

LOCATION

 

OTHER PREMISES

Headquarters, administrative offices operate at the above address. Premises are located at commercial area, lots of transit, construction kept in good condition.
 
Found no premises.

 

 

 

Comments

At corporate level, they hire 5,120 employees.

 

 

FINANCIAL INFORMATION

 

Disposition

C: Poor. Very few information was given. Politely.

Interviewee(s)

Patricio Vargas Muńoz

Position(s)

Finance Corporate Vice President

Information provided

Mr. Vargas provided part of the information in this report which were completed with data from third-party sources.
 
The following is the Interim Balance Sheet for the period ending as of 30/09/2013 (9 months) and the Balance Sheet for the FY ended as of  31/12/2012 and 31/12/2011 (12 months), expressed in Pesos, latest available in public sources.

 

 

INTERIM BALANCE SHEET

Balance Sheet Date

30SEP2013

 

Type of balance sheet

Interim

 

Period

9 months

 

Currency

Pesos

 

Exchange Rate per US$

502.97

 

A S S E T S

 

 

Cash/banks

63,952,635,000.00

 

Receivables

36,577,482,000.00

 

Inventory

90,852,477,000.00

 

Others

88,846,136,000.00

 

Current Assets

280,228,730,000.00

 

Fixed

318,431,815,000.00

 

Others

127,860,507,000.00

 

Total Assets

726,521,052,000.00

 

L I A B I L I T I E S

 

 

Bank/Suppliers

55,478,597,000.00

 

Others

48,005,469,000.00

 

Current liabilities

103,484,066,000.00

 

Long term

275,880,553,000.00

 

S H A R E H O L D E R S'  E Q U I T Y

 

 

Capital

264,207,123,000.00

 

Reserves

-61,928,684,000.00

 

Profit (Loss)

38,448,536,000.00

 

Others

106,429,458,000.00

 

Total shareholders equity

347,156,433,000.00

 

Total liab. / Sh. equity

726,521,052,000.00

 

Sales

288,897,221,000.00

 

Profit (Loss)

38,448,536,000.00

 

 

 

R A T I O

 

Liquidity ratio

2.71

(Current assets / Current liabilities)

Debt-to-equity ratio

335.47 %

(Shareholders' equity / Current liabilities %)

Profitability ratio

13.31 %

(Profits / Sales %)

Working capital

176,744,664,000.00

(Current assets - Current liabilities)

 

 

BALANCE SHEET

Balance sheet date

31DEC2012

31DEC2011

 

Type of balance sheet

Annual

Annual

 

Period

12 months

12 months

 

Currency

Pesos

Pesos

 

Exchange rate per US$

478.6

521.46

 

A S S E T S

 

 

 

Cash/bank

75,212,469,000.00

 

 

Receivables

94,404,329,000.00

 

 

Inventory

71,608,132,000.00

 

 

Others

12,409,140,000.00

 

 

Current Assetsd

253,634,070,000.00

302,376,244,000.00

 

Fixed

96,082,300,000.00

83,407,986,000.00

 

Others

360,794,524,000.00

72,779,474,000.00

 

Total Assets

710,510,894,000.00

458,563,704,000.00

 

L I A B I L I T I E S

 

 

 

Bank/Suppliers

16,722,763,000.00

 

 

Others

79,155,653,000.00

 

 

Current liabilities

95,878,416,000.00

82,409,185,000.00

 

Long term

270,322,374,000.00

21,847,471,000.00

 

TOTAL LIABILITIES

366,200,790,000.00

104,256,656,000.00

 

S H A R E H O L D E R S'  E Q U I T Y

 

 

 

Capital

251,405,708,000.00

 

 

Reserves

-19,874,344,000.00

 

 

Profits (Loss)

37,110,644,000.00

 

 

Others

75,668,096,000.00

 

 

Total shareholders equity

344,310,104,000.00

354,307,048,000.00

 

Total Liab. / Sh. equity

710,510,894,000.00

458,563,704,000.00

 

Sales

273,200,195,000.00

261,384,886,000.00

 

Profit (Loss)

37,110,644,000.00

48,415,296,000.00

 

 

 

R A T I O

 

Liquidity ratio

2.65

Current assets / Current liabilities

Debt-to-equity ratio

359.11 %

(Shareholders' equity / Current liabilities %)

Profitability margin

13.58 %

(Profits / Sales %)

Working capital

157,755,654,000.00

(Current assets - Current liabilities)

 

 

FINANCIAL SITUATION

A+: GOOD
Taking into account the last Financial Statement submitted and/or other factors analyzed, we believe that financial Situation of the Company is GOOD due to the following considerations:
Liquidity Ratio is higher or similar than industry average.  Positive working capital allows the Company to comply with payments promptly. Shareholders' equity covers its current liabilities largely. Final results are positive.

Property of company comments

 

REAL ESTATES. Found no real estates under the Company's name.
VEHICLES.  The Company has no vehicles 

 

 

TRADE REFERENCES, CREDIT BUREAU, LAWSUITS, BANKS

(Confidential Information)

 

TRADE REFERENCES

 

CREDIT BUREAU COMMENTS

No information has been found in the Bulletin of Commercial Information as for protested drafts, promissory notes or checks. Found neither labor or social security infringements nor delinquent debts against the Company.

 

Comments :


BANCO SANTANDER CHILE Under bank secrecy the aforesaid entity did not provide information about its client.

 

 

CREDIT OPINION

 

Consulted Credit Amount :

Maximum Credit

Suggested Credit :

Open



NOTE : The opinion given is confidential, referential and with out liability.

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs. 61.90

UK Pound

1

Rs. 103.25

Euro

1

Rs. 85.13

 

 

INFORMATION DETAILS

 

Report Prepared by :

DPT

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.